Practical considerations in the use of intravenous tacrolimus in hematopoietic stem cell transplantation patients

J Oncol Pharm Pract. 2015 Dec;21(6):478-80. doi: 10.1177/1078155214531609. Epub 2014 Apr 18.

Authors

Tiene Bauters¹, Patricia Rayner², Roxane Therrien³, Sophie Van Lancker⁴, Victoria Bordon⁴, Marion Le Cordroch⁵, Catharina Dhooge⁴, Yves Benoit⁴, Johan Vandenbroucke⁵

Affiliations

¹ Department of Pharmacy, Ghent University Hospital, Ghent, Belgium [email protected].
² Department of Pharmacy, Children's Hospital Michigan, Detroit, MI, USA.
³ Department of Pharmacy, CHU Sainte-Justine, Montreal, Canada.
⁴ Department of Pediatric Hemato-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium.
⁵ Department of Pharmacy, Ghent University Hospital, Ghent, Belgium.

PMID: 24748582
DOI: 10.1177/1078155214531609

No abstract available

Publication types

Letter

MeSH terms

Administration, Intravenous
Graft vs Host Disease / prevention & control
Hematopoietic Stem Cell Transplantation / methods*
Humans
Immunosuppressive Agents / administration & dosage
Immunosuppressive Agents / adverse effects
Immunosuppressive Agents / therapeutic use*
Tacrolimus / administration & dosage
Tacrolimus / adverse effects
Tacrolimus / therapeutic use*

Substances

Immunosuppressive Agents
Tacrolimus